Crossmark

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Published Online: 2023-04-22

Authors

Dubois, Bruno

López‑Arrieta, Jesús

Lipschitz, Stanley

Doskas, Triantafyllos

Spiru, Luiza

Moroz, Svitlana

Venger, Olena

Vermersch, Patrick

Moussy, Alain

Mansfield, Colin D.

Hermine, Olivier

Tsolaki, Magda

,
License Information

Text and Data Mining valid from 2023-04-22

Version of Record valid from 2023-04-22
More Information

Article History

First Online: 22 April 2023

Document is current